On July 2, Novo Nordisk rose 3.09% in regular trading, trading at $50.355/share, with turnover of $112 million. The rally was driven by the continued positive impact of U.S. Medicare beginning coverage of GLP-1 weight-loss drugs on July 1, combined with reports that the company is actively seeking to lower raw material costs from suppliers.

Effective July 1, U.S. Medicare for the first time included GLP-1 weight-loss medications in its standard reimbursement program. Novo Nordisk announced that eligible Medicare patients can now obtain Wegovy for a monthly co-pay of $50, significantly expanding the addressable patient population. The policy applies to patients diagnosed with obesity, defined as a BMI of 30 or above.

Simultaneously, reports indicated Novo Nordisk is pressuring suppliers to reduce raw material prices to maintain competitiveness in the weight-loss drug market, with the company confirming it seeks lower input costs to compete commercially. This dual catalyst of demand expansion through broader insurance access and margin protection through cost discipline supported the stock's outperformance relative to peers, following a 3.18% gain on July 1 when the Medicare policy first took effect.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)